Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56
NCT04199741Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2019
- Primary completion
- Jun 2027
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of [89Zr]Zr-DFO-SC16.56 in small cell lung cancer (SCLC), Neuroendocrine Neoplasm (NEN), prostate cancer (PCa), brain neoplasm, neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2019; status: recruiting.
02
Drugs
[89Zr]Zr-DFO-SC16.56
03
Conditions
small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)prostate cancer (PCa)brain neoplasmneuroblastoma
Beyond the preview
Go deeper on NCT04199741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199741.